The purpose of this study is to compare the systemic levels of beclomethasone 17 monopropionate (17 BMP - the active metabolite of BDP) after intranasal administration of BDP HFA with the systemic levels of 17 BMP after administration of orally inhaled BDP HFA in healthy volunteers.

Inclusion Criteria:

• Informed Consent
• Male or female subjects 18-45 years of age
• General good health

Exclusion Criteria:

• History of physical findings of nasal pathology (within 60 days prior to Screening Visit)
• Participation in any investigational drug study 30 days preceding Screening Visit
• History of respiratory infection/disorder with 28 days preceding Screening Visit